These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28485104)

  • 1. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the
    Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
    Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
    J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 13. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
    Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
    Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
    Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
    Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
    Wang X; Yang B; Ma B
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
    Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
    Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
    Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
    Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.